Avatar - Associated Press
Associated Press
Avatar - Associated Press
Avatar - Associated Press

Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Associated Press

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 20, 2018--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane ® [albumin-bound paclitaxel; nab …

View on apnews.com